Patient Review Survey for Erenumab

What is CADTH? What do they do?

As an independent not-for-profit agency funded by provincial and federal governments, the Canadian Agency for Drugs and Technologies in Health supports informed decisions about the uptake of drugs in Canada.

What is a patient review?

When CADTH evaluates the value of a drug or device, they now welcome the input of patient organizations. CADTH uses this information to better understand the potential value of the new treatments for patients.Their review may influence the reimbursement of drugs by public drug insurers.

What is erenumab?

Erenumab (Aimovig) is a new treatment for migraine. It is an injectable antibody against the CGRP receptor. It is not yet approved by Health Canada.

How can I contribute to this process?

You can fill out our online survey. You will be asked about your experience of living with migraine and your evaluation of currently available treatments. Your data will be anonymous and will be analyzed as group statistics.

Go online at: https://migrainecanada.org/migraine_survey/

Ask us your questions at: info@migrainecanada.org